Werewolf Therapeutics reports Q3 net loss $16.7M; WTX-330 partial response in melanoma

Werewolf Therapeutics, Inc.

2024-Q3 EPS reported -$1.19

Net loss $16.7M for Q3 2024 vs $8.3M in Q3 2023; cash $122.8M, runway through Q2 2026.
WTX-124 monotherapy expansion arms enrolling; initial efficacy data expected H1 2025.
WTX-330 interim data at SITC: 25 patients, 22-fold higher exposure vs rhIL-12, confirmed partial response in melanoma.
New preclinical candidate WTX-921 (IL-10) for inflammatory diseases introduced.
Two WTX-124 patients with confirmed partial responses; one CSCC patient in complete remission >12 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.